Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Account Payables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Account Payables for 16 consecutive years, with $877000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 824.79% to $877000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42000.0 through Dec 2025, up 101.68% year-over-year, with the annual reading at $42000.0 for FY2025, 101.68% up from the prior year.
  • Change in Account Payables for Q4 2025 was $877000.0 at Anika Therapeutics, up from $231000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $1.4 million in Q4 2022, with the low at -$2.9 million in Q3 2024.
  • Average Change in Account Payables over 5 years is -$80500.0, with a median of -$6500.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables plummeted 911.72% in 2024, then skyrocketed 824.79% in 2025.
  • Over 5 years, Change in Account Payables stood at -$398000.0 in 2021, then soared by 459.8% to $1.4 million in 2022, then dropped by 8.66% to $1.3 million in 2023, then plummeted by 109.25% to -$121000.0 in 2024, then surged by 824.79% to $877000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $877000.0, $231000.0, and -$1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.